CGEM Cullinan Management, Inc.

Cullinan Management is advancing a growing portfolio of innovative, early-stage clinical therapeutic assets by capitalizing on the latest scientific breakthroughs. We combine a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs.

$16.26  -0.93 (-5.41%)
As of 12/03/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/13/2009
Outstanding shares:  43,684,540
Average volume:  165,467
Market cap:   $750,937,243
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    230031106
ISIN:        US2300311063
Sedol:      BM90J52
Valuation   (See tab for details)
PE ratio:   -10,118.60
PB ratio:   1.60
PS ratio:   39.64
Return on equity:   -13.85%
Net income %:   -324.14%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy